GlassScriptPhysician profile
Ruth E Baldridge
NPI 1558379834
$2,858.74
in general payments reported to CMS, 2019-2025
20 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $45.27 · 2024: $1,383 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,858.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $692.80 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $551.53 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $510.25 | 2023-2025 | |
| Glaxosmithkline, LLC. | $171.71 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $170.79 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.77 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.27 | 2023-2024 | Jardiance, Ofev |
| Axsome Therapeutics, INC. | $89.28 | 2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $66.17 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Phathom Pharmaceuticals, INC. | $63.91 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $63.69 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $58.94 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $48.66 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $39.75 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $35.43 | 2025 | Eliquis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $23.13 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $21.30 | 2025 | Lagevrio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.63 | 2024 | Caplyta |
| Verona Pharma, INC. | $18.08 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $15.65 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Baldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.